MR imaging in symptomatic tamoxifen-treated patients;Apport de l'IRM chez les patientes symptomatiques traitées par tamoxifène

Journal de Radiologie

Volumn 84, Issue 1, 2003, Pages 33-39

  Taieb S ^a   Ceugnart, L ^a   Chevalier, A ^a   Cabaret, V ^a   Leblanc, E ^a   Fournier, C ^a   Besson, P ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Endometrial carcinoma; MRI; Tamoxifen

Indexed keywords

GADOLINIUM; GADOTERIC ACID; TAMOXIFEN;

ADENOMYOSIS; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HYSTERECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYP; PROSPECTIVE STUDY; TRANSVAGINAL ECHOGRAPHY; UTERUS BLEEDING;

AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATROPHY; BIOPSY; BREAST NEOPLASMS; CONTRAST MEDIA; DECISION TREES; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; MAGNETIC RESONANCE IMAGING; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; POLYPS; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 0037280448     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Early breast cancer trialist's collaborative group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-67.
2. Rose PG. Endometrial carcinoma. The New England Journal of Medicine 1996;335:640-9.
3. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. European Journal of Cancer 1996;32:1464-76.
4. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated patients: finding from the NSABP B-14. Journal of the National Cancer Institute 1994;86:527-37.
5. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? European journal of cancer 1994;11:1714-21.
6. Cuenca RE, Giachino J, Arredondo MA, Hempling R, Edge SB. Endometrial carcinoma associated with breast carcinoma. Cancer 1996;77:2058-63.
7. Ugwumadu AHN, Carmichael PL, Neven P. Tamoxifen and the female genital tract. Int J Gynecol Cancer. 1998;8:6-15.
8. Lasset C, Mignotte H, Bonadona V, Chauvin F. Prognosis of tamoxifen-associated endometrial cancer. J Clin Oncol 1998;16:2573-7.
9. Bertelli G, Venturini M, Del Mastro L et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Research and Treatment 1998;47:41-6.
10. Goldstein S. Unusual ultrasonic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994;170:447-51.
11. Kinkel K, Kaji Y, Yu KK et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999;212:711-8.
12. Ascher SM, Johnson JC, Barnes WA, Bae CJ, Patt RH, Zeman RK. M. imaging appearance of the uterus in postmenopausal women receiving tamoxifen therapy for breast cancer: histopathologic correlation. Radiology 1996;200:105-10.
13. Cecchini S, Ciatto S, Bonardi R et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 1996;60:409-11.
14. Suh-Burgmann EJ, Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med 1999;131:127-35.
15. Cardosi RJ, Fiorica JV. Surveillance of the endometrium in tamoxifen treated women. Curr Opin Obstet gynecol 2000;12:27-31.
16. Koos LG, Schreiber k, Oberlander SG, Moussouris HF, Lesser M. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 1984;64:1-11.
17. M. Seoud, A. Shamseddine, A. Khalil et al. Tamoxifen and endometrial pathologies: a prospective study. Gynecol Oncol. 1999;75:15-9.
18. Barakat RR, Gilewski Ta, Almadrones L, Saigo PE, Venkatraman E, Hoskins WJ. The effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study. Proc Am Soc Clin Oncol 1999;18:358a.
19. Cohen I, Altaras MM, Shapira J et al. Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen. Gynecol Obstet Invest 1997;43:60-3.
20. Kedar RP, Bourne TH, Powles TJ et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;28:1318-21.
21. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999;17:2050-4.
22. Mourits MJ, Van der Zee AG, Willemse PH, Ten Hoor KA, Hollema H, De Vries EG. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 1999;73:21-6.
23. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997;66:233-37.
24. Cohen I, Perel E, Flex D et al. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. J Clin Pathol 1999;52:278-82.
25. Schwartz LB, Snyder J, Horan C, Porges RF, Nachtigall LE, Goldstein SR. The use of sonohysterographie for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen. Ultrasound Obstet Gynecol 1998;11:48-53.
26. Tepper R, Beyth Y, Altaras MM et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifen treated patients. Gynecol Oncol 1997;64:386-91.
27. Bertelli G, Valenzano M, Costantini S et al. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Gynecol Oncol 2000;78:275-7
28. ACOG Committee: Opinion on tamoxifène and endometrial cancer. No 169, Feb.1996.
29. Barakat RR. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer. J Clin Oncol 1999;17:1967-8.
30. Gerber B, Krause A, Muller H et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective longterm study using transvaginal ultrasound. J Clin Oncol 2000;18:3464-70.
31. Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 2000;22:1-11.
32. Berlière M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998;91:40-4.